Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



The prognostic role of the pretreatment peripheral neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in patients with cervical cancer

Sefika Arzu Ergen, Ceren Barlas, Meltem Dagdelen, Gunay Can, Ismet Sahinler.




Abstract
Cited by 0 Articles

Aim: To investigate whether pretreatment peripheral neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) can be used as a prognostic indicator for predicting treatment response and survival outcomes in patients with cervical cancer.
Materials and Methods: Records of 141 patients with histologic confirmation of squamous cell carcinoma of the uterine cervix who were treated with radical radiotherapy or chemoradiotherapy in our clinic from 2010 to 2016 were retrospectively reviewed in this study. The relationship between pretreatment NLR/PLR with clinicopathological characteristics and therapeutic response and survival was analyzed. The cut-off values of NLR and PLR that predicted treatment response were determined using a receiver operating characteristic analysis.
Results: In the clinicopathological analysis, while pretreatment elevated NLR was associated with the tumor size and grade, elevated PLR was related to an advanced stage, tumor size and grade. Low NLR (

Key words: Cervical cancer; neutrophil/lymphocyte ratio; platelet/lymphocyte ratio; radiotherapy; concurrent chemoradiotherapy






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.